New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
08:03 EDTHALOHalozyme announces temporary halt of Phase 2 trial enrollment for PEGPH20
Halozyme announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee, it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer. The DMC is assessing clinical data that indicates a possible difference in the thromboembolic event rate between the group of patients treated with PEGPH20, nab-paclitaxel and gemcitabine versus the group of patients treated with nab-paclitaxel and gemcitabine without PEGPH20. The company is halting enrollment and dosing of PEGPH20 as precautionary actions while the DMC's full evaluation of the data is ongoing.
News For HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:34 EDTHALOHalozyme receives EU Orphan Drug designation for PEGPH20
Subscribe for More Information
December 17, 2014
09:13 EDTHALOHalozyme up nearly 5% after announcing collaboration pact with Janssen
Subscribe for More Information
09:04 EDTHALOHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
09:02 EDTHALOHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use